Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

NCT06120556 · Completed

Last updated 2026-05-28

This clinical trial is testing how well a class of diabetes medications called GLP-1 receptor agonists works in people with type 2 diabetes, grouped by different subtypes of the disease.

Status Completed The study has finished.

Type Observational

Participants 130 people

Who can join Ages 50+ · all sexes

Timeline Started 2023-06 · est. completion 2023-10

Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT06120556 ↗

Description as written by the study sponsor.

The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with type 2 diabetes. The main questions it aims to answer are: * people with type 2 diabetes belonging to specific subtypes respond better (or worse) to GLP-1RA? * the beneficial effect of GLP-1RA may last longer in people with type 2 diabetes belonging to specific subtypes? * what are the clinical characteristics that better explain the efficacy and durability of GLP-1 receptor agonists in type 2 diabetes management? Clinical data from records of patients attending the diabetes outpatient clinic of our facility will be retrieved to compare the outcomes of GLP-1 receptor agonists in patients belonging to four subtypes of type 2 diabetes.

Treatments tested

GLP-1 receptor agonist Drug

Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.

Main thing measured	Difference in HbA1c change from baseline (%) among SIDD, SIRD, MARD, MOD subtypes
Sponsor	Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06120556 ↗